

(Modified) PTØ/SR/08A-B (10-96)
Approved for use through 10/31/99. Over 0651-0031

Application Number 09/704469

Filing Date November 1, 2000

First Named Inventor Erik Karrer

Group Art Unit Unassigned

Examiner Name Unassigned

Attorney Docket Number 02-102020US

(use as many sheets as necessary)

			Ū.	S. PATENT DOCUMENTS		/
Examiner Initials	Cite No.	U.S. Patent Docum Number		Name of Patentee or Applicant of Cited Document	Oate of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	AA	09/407,808	·	Maxygen, Inc.	09-28-1999	
	AB	09/408,392		Maxygen, Inc.	09-28-1998	
	AC	09/408,393		Maxygen, Inc	09-28-1999	
	AD	09/618,579		Maxygen, Inc.	07-16-2000	
	ΑE	60/186,482		Maxygen, Inc.	08-02-2000	
	AF	4,634,664		Engelman et al.	01-06-1987	
	AG	4,634,666		Engelman et al.	01-06-1987	
	АН	5,756,316		Schellenberger	05-26-1998	
	ΑI	5,783,431		Peterson et al.	07-21-1998	
	AJ	5,824,485		Thompson et al.	10-20-1998	

				FOREIG	N PATENT OOCUMEN			
Examiner	Cite		Foreign Patent Docum	ent Kind Code	Name of Palentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т
Initials	No.	Office	Number	(if known)	Applicant of Cited Document	MM-DD-YYYY	or Relevant Figures Appear	_
	AK	wo	00/00632	A1 /	Phylos, Inc	01-06-2000		_
	AL	wo	00/09676	A1	Proteus	02-24-2000		<u> </u>
	AM	wo	00/42560	1/2	Maxygen, Inc.	07-20-2000		L
	AN	wo	00/42560	А3	Maxygen, Inc.	0720-2000		_
	AO	wo	00/42561	A2	Maxygen, Inc.	07-20 2000		
	AP	wo	00/42591	- A3	Maxygen, Inc.	07-20-2000		<u> </u>
	AQ	wo	00/46344	A2	Diversa Corp.	08-10-2000		
	AR	wo	90/46344	A3	Diversa Corp.	08-10-2000		
	AS	wo /	00/42559	A1.	Maxygen, Inc.	07-20-2000		
	AT	wø	95/22625	A1	Stemmer	08-24-1995		
	AU	WO	96/33207	A1	Stemmer	10-24-1996		
	Ay	wo	97/35957	A1	Stemmer	10-02-1997		
	AW	wo	98/42727	A1	SRI International	10-01-1998		

Examiner Signature	/Eric Dejong/	Date Considered	01/18/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTC/SCDRA-B (10-96)
Approved for use through 10/31/99. On P 15-1-0031

Core	tituda f-	r form 1449A-B/RTO	T	Complete if Known	4	
Substitute for form 1449A-B/PTO			Application Number	09/704469	<u> </u>	
1		ATION DISCLOSURE	Filing Date	November 1, 2000		
INFORMATION DISCLOSURE			First Named Inventor	Erik Karrer		
STATEMENT BY APPLICANT		ENT BY APPLICANT	Group Art Unit	Unassigned		
	- \					
	íuse as	many sheets as necessary)	Examiner Name	Unassigned	_	
		\ '	Attorney Docket Number			
		OTHER PRIOR ART	NON PATENT LITERATU	THE DOCUMENTS ,	т-	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL exital, symposium, catalog, etc.), da	LETTERS), title of the article (when ap te, page(s), volume-issue number(s),	propriate), title of the item (book, magazine, journal, publisher, city and/or country where published.		
	ΑX	Balint and Larrick (1993) "Anti 137:109-118	body Engineering by Parsi	monious Mutagepesis." Gene		
	AY	Chothia and Lesk (1987) "Can Immunoglobuline." J Mol Biol.	ionical Structures for the H 196:901-917	ypervariable Regions of		
	ΑZ	Giver et al. (1998) Combinato Chemical Biology 2(3): 335-3:	oral protein design by in vitr 38.	ro recombination." Current Opinion in		
	ВА	Gram et al. (1992) "In Vitro sel combinatorial immunoglobylin	lection and affinity maturati library." PNAS 89:3576-35	or of antibodies from a naïve		
	ВВ	Hawkins et al. (1992) "Select maturation." J. Mol Biol. 226:8		by binding affinity. Mimicking affinity		
	вс	Hock (1997) "Antibodies for immunosensors: a review." Analytica Chimica Acta 347:177-186 Huse et al. (1989) "Generation of a Large Combinational Library of the Immunoglobulin Repertoire in Phage Lambda." Science 246(1275-1281)				
	BD					
	BE	Jirholt et al. (1998) "Exploiting sequence space: shuffling in vivo formed complementarily determining regions into a master framework." Gene 215:471-476				
	BF	Litman et al. (1993) "Phylogen repertoire." <i>Mol Biol Evol</i> 10:60		unoglobulin genes and the antibody		
displayed on bacteriophage BH Marks et al. (1991) "By-p		Low et al. (1996) "Mimicking of displayed on bacteriophage us	opmatic hypermutation: attinity maturation of antibodies using a bacterial mutator stigin." <i>J. Mol Biol.</i> 260:359-368			
		Marks et al. (1991) "By-pas displayed on phage." . Mol Bi		antibodies from V-gene libraries		
	ВІ	Marks et al. (1992) By-Passin Chain Shuffling." Biotechnique		ligh Afficity Human Antibodies by		
	BJ	BIAcore guided selections." Hum Antibodies Hybridomas 7:95-105				
	вк					
	BL	Stemmer et al. (1995) "Single- of oligodeoxy-ribonucleotides."		nd entire plasmid form large numbers		
	ВМ	Stemmer et al. (1997) "Molecu J. 11:A1124	lar evolution of genes and	pathways by DNA shuffling. FASEB		
	BN	Ward et al. (1989) "Binding act domains secreted from Eschei				

Examiner Signature	/Eric Dejong/	Date Considered	01/18/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Modified) PTO/SB/08/08 (10-96) Approved for use through 10/31/99. OMB 0531-0031

Substitute for form 1449A-B/PTO		C	Complete if Known		
\		Application Number	09/704469		
V PORM	ATION DISCLOSURE	Filing Date	November 1, 2000		
STATEM	ENT BY APPLICANT	First Named Inventor	Erik Karrer		
		Group Art Unit	Unassigned		
(use as many sheets as necessary)		Examiner Name	Unassigned		
		Attorney Docket Number	02-102020US		
ВО	12:433-455		Technology." Annu Rev. Immunol		
BP			able regions of bence jones proteins ody complementarity." J. Exo Med.		

Examiner /Eric Dejong/ Date Consid	te 01/18/2007 nsidered
------------------------------------	---------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include-copy of this form with next communication to applicant.